Clinical Research Directory
Browse clinical research sites, groups, and studies.
SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers
Sponsor: University of Patras
Summary
Study of the response to SGLT2 inhibitors in type 2 diabetic patients with relevance to the erythropoesis and indexes of cardiorenal function. The study enrolls type 2 diabetic patients in whom the introduction of a SGLT2 inhibitor is deemed necessary as part of their routine treatment during their visit to our outpatient diabetes unit. A whole blood, a serum and a urine sample is obtained before and one month after the initiation of treatment with a SGLT2 inhibitor.
Official title: Study of the Mechanisms Leading to Increased Hemoglobin Levels and of the Cardiorenal Response in Type 2 Diabetic Patients With Recent Initiation of SGLT2 Inhibitors.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
80
Start Date
2022-06-03
Completion Date
2024-06-01
Last Updated
2024-05-14
Healthy Volunteers
No
Conditions
Interventions
SGLT2 inhibitor
Patients receive an SGLT2 inhibitor as part of theirn routine care.
Locations (1)
University Hospital of Patras
Pátrai, Greece